Literature DB >> 20700738

FDG PET/CT for monitoring response to neoadjuvant chemotherapy in breast cancer patients.

Katharina Dalus, Gundula Rendl, Lukas Rettenbacher, Christian Pirich.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20700738     DOI： 10.1007/s00259-010-1585-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  8 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study.

Authors:  Igor Langer; Ulrich Guller; Carsten T Viehl; Holger Moch; Edward Wight; Felix Harder; Daniel Oertli; Markus Zuber
Journal:  Ann Surg Oncol       Date:  2009-09-04       Impact factor: 5.344

3.  Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.

Authors:  M R Machiavelli; A O Romero; J E Pérez; J A Lacava; M E Domínguez; R Rodríguez; M R Barbieri; L A Romero Acuña; J M Romero Acuña; M J Langhi; S Amato; E H Ortiz; C T Vallejo; B A Leone
Journal:  Cancer J Sci Am       Date:  1998 Mar-Apr

4.  Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography.

Authors:  Caroline Rousseau; Anne Devillers; Christine Sagan; Ludovic Ferrer; Boumédiène Bridji; Loïc Campion; Myriam Ricaud; Emmanuelle Bourbouloux; Isabelle Doutriaux; Martine Clouet; Dominique Berton-Rigaud; Catherine Bouriel; Valérie Delecroix; Etienne Garin; Sophie Rouquette; Isabelle Resche; Pierre Kerbrat; Jean François Chatal; Mario Campone
Journal:  J Clin Oncol       Date:  2006-11-06       Impact factor: 44.544

5.  [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy.

Authors:  Alina Berriolo-Riedinger; Claude Touzery; Jean-Marc Riedinger; Michel Toubeau; Bruno Coudert; Laurent Arnould; Christophe Boichot; Alexandre Cochet; Pierre Fumoleau; François Brunotte
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06-20       Impact factor: 9.236

6.  Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose.

Authors:  Jörg Schwarz-Dose; Michael Untch; Reinhold Tiling; Stefanie Sassen; Sven Mahner; Steffen Kahlert; Nadia Harbeck; Annette Lebeau; Winfried Brenner; Markus Schwaiger; Fritz Jaenicke; Norbert Avril
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

7.  18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer.

Authors:  Joan Duch; David Fuster; Montserrat Muñoz; Pedro Luís Fernández; Pilar Paredes; Montserrat Fontanillas; Flavia Guzmán; Sebastià Rubí; Francisco Juan Lomeña; Francesca Pons
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-27       Impact factor: 9.236

8.  Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer.

Authors:  A H Honkoop; P J van Diest; J S de Jong; S C Linn; G Giaccone; K Hoekman; J Wagstaff; H M Pinedo
Journal:  Br J Cancer       Date:  1998-02       Impact factor: 7.640
  8 in total
  4 in total

1.  Early and delayed prediction of axillary lymph node neoadjuvant response by (18)F-FDG PET/CT in patients with locally advanced breast cancer.

Authors:  Ana María García Vicente; Ángel Soriano Castrejón; Alberto León Martín; Fernanda Relea Calatayud; María Del Mar Muñoz Sánchez; Miguel Ángel Cruz Mora; Germán Andrés Jiménez Londoño; Ruth Espinosa Aunión
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-04-18       Impact factor: 9.236

2.  Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients.

Authors:  C Riegger; J Herrmann; J Nagarajah; J Hecktor; S Kuemmel; F Otterbach; S Hahn; A Bockisch; T Lauenstein; G Antoch; T A Heusner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03-06       Impact factor: 9.236

3.  FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients.

Authors:  Caroline Rousseau; Anne Devillers; Mario Campone; Loïc Campion; Ludovic Ferrer; Christine Sagan; Myriam Ricaud; Boumédiène Bridji; Françoise Kraeber-Bodéré
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-02-10       Impact factor: 9.236

4.  Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer.

Authors:  Mette S van Ramshorst; Suzana C Teixeira; Bas B Koolen; Kenneth E Pengel; Kenneth G Gilhuijs; Jelle Wesseling; Sjoerd Rodenhuis; Renato A Valdés Olmos; Emiel J Rutgers; Wouter V Vogel; Gabe S Sonke; Marie-Jeanne T Vrancken Peeters
Journal:  Cancer Imaging       Date:  2017-05-25       Impact factor: 3.909
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.